← Pulse/Companies

Encore Medical on Pulse

Biotech

The full thread of our Encore Medical coverage — a running record of every development we've tracked, with the VC take on each.

2
Stories
2
With a headline figure
Jun 30, 2026
Since

Coverage Timeline

newest first
  1. IPOEncore Medical Files Amended S-1 to Fund US Trials for Its Heart-Defect Closure Device→
  2. IPOEncore Medical Prices Structural Heart IPO at $5/Share on NYSE American as Cash Runway Tightens→

All Coverage

IPO~$12.6M-$14.67M

Encore Medical Files Amended S-1 to Fund US Trials for Its Heart-Defect Closure Device

Encore Medical filed an amended S-1 on July 1 ahead of a planned NYSE American listing under ticker EMI, offering 3 million shares at an expected $5.00 each to raise roughly $12.6-14.67 million to fund US clinical trials for its catheter-delivered heart-defect closure device, which has completed more than 35,000 implants outside the United States but has not yet been approved for US sale. Underwriters BofA Securities, Goldman Sachs and Morgan Stanley are jointly leading the offering.

Jul 1, 2026
IPO$5.00/share IPO

Encore Medical Prices Structural Heart IPO at $5/Share on NYSE American as Cash Runway Tightens

Encore Medical, a structural heart device company developing transcatheter septal occlusion products, filed its latest S-1/A on June 30, targeting an IPO of 3 million shares at an expected $5 per share on NYSE American under ticker EMI. The company's cash balance stood at just $34,619 as of March 31, 2026, underscoring how urgently it needs the offering to fund ongoing US clinical trials.

Jun 30, 2026